BioSpace News Archive

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel drugs for immuno-inflammatory diseases, announced an exclusive patent license agreement with Sun Pharmaceutical Industries, Inc.

BioCryst Pharmaceuticals, Inc. announced that the compensation committee of BioCryst’s board of directors granted 16 newly-hired employees stock options to purchase an aggregate of 74,500 shares, and restricted stock units covering an aggregate of 51,050 shares, of BioCryst common stock.

The global immunotherapy drugs market size was estimated at around USD 202.67 billion in 2022 and it is projected to hit around USD 1,063.44 billion by 2032, growing at a CAGR of 18.03% from 2023 to 2032.

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that Health Canada has granted expanded authorization for Nuvaxovid™ XBB.1.5 Vaccine (Recombinant protein, Adjuvanted) (NVX-CoV2601) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals aged 12 and older.

Align Technology, Inc. announced that its Board of Directors has appointed Mojdeh Poul, former EVP and Group President of 3M Health Care, and Kevin Conroy, President, Chief Executive Officer, and Chairman of the Board of Exact Sciences.

ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced the appointment of Paul Perreault to its Board of Directors, effective December 5, 2023.

Medicure Inc. through its pharmacy subsidiary Marley Drug®, a trusted national pharmacy known for its commitment to affordable healthcare solutions, is pleased to announce a partnership with TheracosBio to distribute a newly approved diabetes drug, BRENZAVVY® tablets, a sodium-glucose cotransporter-2 inhibitor, at an affordable cash price delivered directly to patient homes in all 50 US states and territories.

Merck KGaA, Darmstadt, Germany today announced that its two Phase III EVOLUTION clinical trials (evolutionRMS 1 and evolutionRMS 2) investigating the efficacy and safety of evobrutinib did not meet their primary endpoints of reducing annualized relapse rates (ARR) in people with relapsing multiple sclerosis (RMS) compared to oral teriflunomide (0.11 vs. 0.11 in evolutionRMS 1 and 0.15 for evobrutinib and 0.14 for teriflunomide in evolutionRMS 2, p=NS in both trials)

GC Biopharma, a South Korean biopharmaceutical company, announced on December 6th that it has participated in the groundbreaking ceremony of a plasma fractionation plant held at Jababeka Industrial Estate in Indonesia, one of the company’s overseas plant construction projects.

Novartis today announced that the U.S. Food and Drug Administration (FDA) approved Fabhalta® (iptacopan) as the first oral monotherapy for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH)1.